drugset / Trial / NCT07036029
NAL ER IPF Respiratory Function and Safety Study
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Timeline
- Start
- 2025-08-21
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | — | Oral |